4 completed, 1 terminated, 1 unknown. 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Terminated 1, Unknown 1 |
Follow Palobiofarma SL: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers. PBF-1650 oral capsules, Placebo oral capsule - Psoriasis | Phase 1 | Completed | Palobiofarma SL | 32 | 2018-12-10 | 2020-06-30 |
| PBF-1129 in Patients With NSCLC PBF-1129 - Locally Advanced or Metastatic NSCLC | Phase 1 | Unknown | Palobiofarma SL | 18 | 2018-10-01 | 2024-02-09 |
| Study of PBF-999 in Solid Tumour Advanced Cancer PBF-999 - Cancer | Phase 1 | Completed | Palobiofarma SL | 54 | 2017-10-01 | 2023-01-26 |
| Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers PBF-999 / 160 mg, PBF-999 / 320 mg, Placebo - Huntington Disease | Phase 1 | Terminated | Palobiofarma SL | 8 | 2016-03-01 | 2016-09-20 |
| "First-in-human" Study To Assess the Safety and Tolerability of PBF-677 in Healthy Volunteers PBF-677, Placebo - Glaucoma | Phase 1 | Completed | Palobiofarma SL | 32 | 2015-12-01 | 2018-12-17 |
| Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) PBF-509_80 mg, PBF-509_160 mg, PBF-509_320 mg - Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Completed | Palobiofarma SL | 92 | 2015-10-01 | 2022-01-12 |
Carcinoma, Non-Small-Cell Lung (2) · Autoimmune Diseases (1) · Glaucoma (1) · Huntington Disease (1) · Mental Disorders (1) · Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Psoriasis (1)
spartalizumab (1)
Spain (3) · United States (2)
Alberto Chiappori, MD (1) · Joan Martinez, MD (1)
2015 (1)